Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa.
Price History & Performance
|Historical stock prices|
|Current Share Price||€411.50|
|52 Week High||€199.00|
|52 Week Low||€397.50|
|1 Month Change||7.16%|
|3 Month Change||24.32%|
|1 Year Change||90.07%|
|3 Year Change||189.79%|
|5 Year Change||183.79%|
|Change since IPO||3,248.79%|
Recent News & Updates
Is Virbac (EPA:VIRP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|VIRP||FR Pharmaceuticals||FR Market|
Return vs Industry: VIRP exceeded the French Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: VIRP exceeded the French Market which returned 35.2% over the past year.
Stable Share Price: VIRP is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: VIRP's weekly volatility (5%) has been stable over the past year.
About the Company
Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Virbac Fundamentals Summary
|VIRP fundamental statistics|
Is VIRP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VIRP income statement (TTM)|
|Cost of Revenue||€333.83m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||19.31|
|Net Profit Margin||16.54%|
How did VIRP perform over the long term?See historical performance and comparison
0.2%Current Dividend Yield
Is Virbac undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: VIRP (€385) is trading below our estimate of fair value (€385.63)
Significantly Below Fair Value: VIRP is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: VIRP's PE Ratio (19.9x) is in line with the French Pharmaceuticals industry average.
PE vs Market: VIRP is poor value based on its PE Ratio (19.9x) compared to the French market (19.5x).
Price to Earnings Growth Ratio
PEG Ratio: VIRP is poor value based on its PEG Ratio (7x)
Price to Book Ratio
PB vs Industry: VIRP is overvalued based on its PB Ratio (4.6x) compared to the FR Pharmaceuticals industry average (3.6x).
How is Virbac forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIRP's forecast earnings growth (2.8% per year) is above the savings rate (0.3%).
Earnings vs Market: VIRP's earnings (2.8% per year) are forecast to grow slower than the French market (12.3% per year).
High Growth Earnings: VIRP's earnings are forecast to grow, but not significantly.
Revenue vs Market: VIRP's revenue (4.7% per year) is forecast to grow slower than the French market (6.2% per year).
High Growth Revenue: VIRP's revenue (4.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VIRP's Return on Equity is forecast to be low in 3 years time (13.7%).
How has Virbac performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VIRP has a large one-off gain of €66.9M impacting its June 30 2021 financial results.
Growing Profit Margin: VIRP's current net profit margins (16.5%) are higher than last year (7.6%).
Past Earnings Growth Analysis
Earnings Trend: VIRP's earnings have grown significantly by 47.8% per year over the past 5 years.
Accelerating Growth: VIRP's earnings growth over the past year (125.6%) exceeds its 5-year average (47.8% per year).
Earnings vs Industry: VIRP earnings growth over the past year (125.6%) exceeded the Pharmaceuticals industry 10.2%.
Return on Equity
High ROE: VIRP's Return on Equity (22.8%) is considered high.
How is Virbac's financial position?
Financial Position Analysis
Short Term Liabilities: VIRP's short term assets (€638.7M) exceed its short term liabilities (€356.2M).
Long Term Liabilities: VIRP's short term assets (€638.7M) exceed its long term liabilities (€106.5M).
Debt to Equity History and Analysis
Debt Level: VIRP's debt to equity ratio (12.4%) is considered satisfactory.
Reducing Debt: VIRP's debt to equity ratio has reduced from 134.6% to 12.4% over the past 5 years.
Debt Coverage: VIRP's debt is well covered by operating cash flow (128.4%).
Interest Coverage: VIRP's interest payments on its debt are well covered by EBIT (26.1x coverage).
What is Virbac current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: VIRP's dividend (0.19%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.32%).
High Dividend: VIRP's dividend (0.19%) is low compared to the top 25% of dividend payers in the French market (3.93%).
Stability and Growth of Payments
Stable Dividend: VIRP is not paying a notable dividend for the French market, therefore no need to check if payments are stable.
Growing Dividend: VIRP is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: VIRP is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VIRP's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sebastien Huron (50 yo)
Mr. Sebastien Huron has been Chairman of Executive Board at Virbac SA since December 20, 2017. He served as the Head of Global Business Operations at Virbac SA since 2014 and has been its Member of Executi...
CEO Compensation Analysis
Compensation vs Market: Sebastien's total compensation ($USD674.47K) is below average for companies of similar size in the French market ($USD1.63M).
Compensation vs Earnings: Sebastien's compensation has been consistent with company performance over the past year.
Experienced Management: VIRP's management team is considered experienced (2.3 years average tenure).
Experienced Board: VIRP's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Virbac SA's employee growth, exchange listings and data sources
- Name: Virbac SA
- Ticker: VIRP
- Exchange: ENXTPA
- Founded: 1968
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €3.251b
- Shares outstanding: 8.44m
- Website: https://corporate.virbac.com
Number of Employees
- Virbac SA
- 13e rue LID - BP 27
- Provence-Alpes-Côte d'Azur
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 18:01|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.